Binding of [3H]naloxonazine to rat brain membranes

N Johnson and GW Pasternak

[3H]Naloxonazine binds to opioid-binding sites in rat brain homogenates. Prior administration of either morphine or D-Ala2-D-Leu5- enkephalin to the homogenates inhibits in a concentration-dependent manner the specific binding of [3H]naloxonazine. Most important, all the binding competed by unlabeled naloxonazine at 1 microM is also competed by morphine and D-Ala2-D-Leu5-enkephalin. [3H]Naloxonazine binding is linear with tissue up to 10 mg/ml wet weight of tissue, is temperature dependent, and has a pH maximum of approximately 7.7. Maximal binding is reached within 90 min at 25 degrees. The affinity of [3H]naloxonazine for its binding sites is quite high with half-maximal binding obtained at a concentration of approximately 2 nM. Approximately 40% of the total specific binding of [3H]naloxonazine is resistant to multiple washes and to displacement by levallorphan (1 microM) added 60 min after the [3H]naloxonazine, suggesting that a portion of [3H]naloxonazine binding is not freely reversible. The percentage of total [3H] naloxonazine binding which is not freely reversible varies 3-fold between regions, with the hypothalamus (60%) being the highest and the brainstem (18%) the lowest.

Volume 26, Issue 3, pp. 477-483, 11/01/1984
Copyright © 1984 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				G. Tanda, F. E. Pontieri, and G. D. Chiara Cannabinoid and Heroin Activation of Mesolimbic Dopamine Transmission by a Common µ1 Opioid Receptor Mechanism Science, June 27, 1997; 276(5321): 2048 - 2050. [Abstract] [Full Text]